Robert L. Doyle, D.D.S., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Attention Deficit Disorder with Hyperactivity | 24 | 2016 | 3717 | 0.960 |
Why?
|
| Child Development Disorders, Pervasive | 5 | 2014 | 597 | 0.710 |
Why?
|
| Methylphenidate | 10 | 2012 | 480 | 0.580 |
Why?
|
| Central Nervous System Stimulants | 9 | 2012 | 1167 | 0.460 |
Why?
|
| Rett Syndrome | 1 | 2014 | 163 | 0.420 |
Why?
|
| Nerve Growth Factors | 1 | 2014 | 564 | 0.380 |
Why?
|
| Cerebellum | 1 | 2016 | 1519 | 0.310 |
Why?
|
| Propylamines | 4 | 2010 | 161 | 0.310 |
Why?
|
| Brain Diseases | 1 | 2016 | 1550 | 0.280 |
Why?
|
| Esophagectomy | 1 | 2009 | 477 | 0.250 |
Why?
|
| Indans | 1 | 2006 | 92 | 0.250 |
Why?
|
| Mast Cells | 2 | 2008 | 1411 | 0.230 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2006 | 241 | 0.220 |
Why?
|
| Personality Inventory | 1 | 2007 | 1018 | 0.220 |
Why?
|
| Delayed-Action Preparations | 11 | 2012 | 967 | 0.210 |
Why?
|
| Autistic Disorder | 2 | 2008 | 1239 | 0.190 |
Why?
|
| Blood-Brain Barrier | 1 | 2008 | 1037 | 0.190 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2003 | 187 | 0.190 |
Why?
|
| Adrenergic Uptake Inhibitors | 4 | 2010 | 187 | 0.190 |
Why?
|
| Pulmonary Artery | 1 | 2008 | 1935 | 0.170 |
Why?
|
| Esophageal Neoplasms | 1 | 2009 | 1662 | 0.160 |
Why?
|
| Bipolar Disorder | 7 | 2011 | 5127 | 0.160 |
Why?
|
| Survivors | 1 | 2009 | 2374 | 0.160 |
Why?
|
| Antidepressive Agents, Second-Generation | 3 | 2010 | 490 | 0.150 |
Why?
|
| Anticonvulsants | 2 | 2010 | 1919 | 0.150 |
Why?
|
| Hypertension, Pulmonary | 1 | 2008 | 1603 | 0.140 |
Why?
|
| Piperidines | 1 | 2006 | 1662 | 0.140 |
Why?
|
| Caregivers | 1 | 2009 | 2306 | 0.140 |
Why?
|
| Antimanic Agents | 2 | 2011 | 523 | 0.140 |
Why?
|
| Dopamine Uptake Inhibitors | 2 | 2012 | 287 | 0.140 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 5 | 2011 | 1987 | 0.130 |
Why?
|
| Hyperkinesis | 1 | 2016 | 88 | 0.130 |
Why?
|
| Psychomotor Disorders | 1 | 2016 | 149 | 0.120 |
Why?
|
| Psychiatric Status Rating Scales | 9 | 2010 | 6015 | 0.120 |
Why?
|
| Insulin Resistance | 1 | 2008 | 3989 | 0.120 |
Why?
|
| PubMed | 1 | 2014 | 130 | 0.110 |
Why?
|
| Impulsive Behavior | 1 | 2016 | 344 | 0.110 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 1 | 2014 | 184 | 0.110 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2014 | 362 | 0.100 |
Why?
|
| Drug Administration Schedule | 7 | 2010 | 4850 | 0.100 |
Why?
|
| Adolescent | 22 | 2016 | 88804 | 0.100 |
Why?
|
| Epilepsy | 2 | 2008 | 3317 | 0.100 |
Why?
|
| Interview, Psychological | 2 | 2011 | 811 | 0.090 |
Why?
|
| Signal Transduction | 1 | 2014 | 23590 | 0.090 |
Why?
|
| Dibenzothiazepines | 1 | 2011 | 101 | 0.090 |
Why?
|
| Child | 20 | 2016 | 80510 | 0.090 |
Why?
|
| Memantine | 1 | 2012 | 110 | 0.090 |
Why?
|
| Osmosis | 1 | 2010 | 103 | 0.090 |
Why?
|
| Personality Assessment | 2 | 2010 | 646 | 0.090 |
Why?
|
| Bupropion | 2 | 2003 | 303 | 0.090 |
Why?
|
| Reaction Time | 1 | 2016 | 2086 | 0.080 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2012 | 450 | 0.080 |
Why?
|
| Female | 37 | 2016 | 396159 | 0.080 |
Why?
|
| Carbamazepine | 1 | 2010 | 224 | 0.080 |
Why?
|
| Male | 37 | 2016 | 363808 | 0.080 |
Why?
|
| Neuropsychological Tests | 5 | 2016 | 7121 | 0.070 |
Why?
|
| Brain | 2 | 2014 | 27177 | 0.070 |
Why?
|
| Triazines | 1 | 2010 | 306 | 0.070 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 2007 | 28 | 0.070 |
Why?
|
| Asperger Syndrome | 2 | 2010 | 57 | 0.070 |
Why?
|
| Adolescent Behavior | 2 | 2007 | 1185 | 0.070 |
Why?
|
| Treatment Outcome | 17 | 2012 | 65236 | 0.070 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2012 | 896 | 0.070 |
Why?
|
| Psychometrics | 4 | 2011 | 3060 | 0.070 |
Why?
|
| Juvenile Delinquency | 1 | 2007 | 115 | 0.070 |
Why?
|
| Attitude to Death | 1 | 2009 | 400 | 0.070 |
Why?
|
| Obsessive-Compulsive Disorder | 2 | 2006 | 1485 | 0.060 |
Why?
|
| Humans | 42 | 2016 | 766011 | 0.060 |
Why?
|
| Problem Solving | 1 | 2008 | 440 | 0.060 |
Why?
|
| Behavior | 1 | 2008 | 535 | 0.060 |
Why?
|
| Biological Transport | 1 | 2008 | 2079 | 0.060 |
Why?
|
| Reading | 1 | 2008 | 540 | 0.060 |
Why?
|
| Tics | 1 | 2004 | 76 | 0.060 |
Why?
|
| Quinolones | 1 | 2007 | 387 | 0.060 |
Why?
|
| Self Concept | 1 | 2009 | 1038 | 0.050 |
Why?
|
| Checklist | 1 | 2010 | 847 | 0.050 |
Why?
|
| Tourette Syndrome | 1 | 2004 | 400 | 0.050 |
Why?
|
| Comorbidity | 5 | 2010 | 10572 | 0.050 |
Why?
|
| Pregnancy | 1 | 2003 | 30253 | 0.050 |
Why?
|
| Triglycerides | 1 | 2008 | 2440 | 0.040 |
Why?
|
| Heart Rate | 2 | 2009 | 4203 | 0.040 |
Why?
|
| Mental Disorders | 4 | 2010 | 6873 | 0.040 |
Why?
|
| Amphetamines | 1 | 2001 | 143 | 0.040 |
Why?
|
| Prospective Studies | 12 | 2012 | 54818 | 0.040 |
Why?
|
| Gastrointestinal Diseases | 1 | 2008 | 1203 | 0.040 |
Why?
|
| Cytokines | 1 | 2014 | 7425 | 0.040 |
Why?
|
| Anxiety Disorders | 2 | 2010 | 2740 | 0.040 |
Why?
|
| Social Support | 1 | 2009 | 2191 | 0.040 |
Why?
|
| Social Behavior | 1 | 2006 | 1143 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2009 | 2660 | 0.040 |
Why?
|
| Intention to Treat Analysis | 2 | 2010 | 416 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2003 | 1416 | 0.040 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2007 | 1899 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2008 | 6838 | 0.040 |
Why?
|
| Child Behavior | 1 | 2004 | 864 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2008 | 4190 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2004 | 1573 | 0.040 |
Why?
|
| Severity of Illness Index | 7 | 2010 | 15887 | 0.040 |
Why?
|
| Middle Aged | 15 | 2012 | 223058 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2010 | 3616 | 0.030 |
Why?
|
| Follow-Up Studies | 9 | 2010 | 39226 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 2206 | 0.030 |
Why?
|
| Piperazines | 1 | 2007 | 2546 | 0.030 |
Why?
|
| Adult | 16 | 2012 | 223109 | 0.030 |
Why?
|
| Blood Pressure | 2 | 2009 | 8537 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2007 | 2694 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2010 | 10731 | 0.030 |
Why?
|
| Psychotropic Drugs | 1 | 2002 | 881 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2004 | 2761 | 0.030 |
Why?
|
| Chi-Square Distribution | 3 | 2009 | 3436 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2007 | 2778 | 0.030 |
Why?
|
| Time Factors | 4 | 2012 | 40117 | 0.030 |
Why?
|
| Case-Control Studies | 3 | 2008 | 22230 | 0.030 |
Why?
|
| Risk Factors | 5 | 2012 | 74870 | 0.030 |
Why?
|
| Pediatrics | 1 | 2010 | 3604 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 2005 | 1659 | 0.030 |
Why?
|
| Antidepressive Agents | 1 | 2007 | 2903 | 0.030 |
Why?
|
| Double-Blind Method | 5 | 2010 | 12433 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 2007 | 3713 | 0.030 |
Why?
|
| Placebos | 3 | 2005 | 1659 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2007 | 15403 | 0.030 |
Why?
|
| Drug Therapy, Combination | 3 | 2009 | 6307 | 0.030 |
Why?
|
| Cognition Disorders | 1 | 2007 | 3968 | 0.030 |
Why?
|
| Logistic Models | 1 | 2007 | 13271 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2008 | 6274 | 0.020 |
Why?
|
| Antipsychotic Agents | 1 | 2005 | 3076 | 0.020 |
Why?
|
| Communication | 1 | 2006 | 3913 | 0.020 |
Why?
|
| Risperidone | 2 | 2005 | 383 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2007 | 14751 | 0.020 |
Why?
|
| Mutation | 1 | 2014 | 30187 | 0.020 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 1 | 2010 | 305 | 0.020 |
Why?
|
| Age Factors | 4 | 2010 | 18384 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2009 | 527 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2010 | 1605 | 0.020 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2007 | 108 | 0.020 |
Why?
|
| Aged | 3 | 2009 | 171233 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2012 | 8733 | 0.020 |
Why?
|
| Drug Substitution | 1 | 2010 | 292 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2007 | 16040 | 0.020 |
Why?
|
| Reproducibility of Results | 3 | 2011 | 20125 | 0.020 |
Why?
|
| Systole | 1 | 2009 | 935 | 0.020 |
Why?
|
| Diastole | 1 | 2009 | 785 | 0.020 |
Why?
|
| Schizophrenia | 1 | 2005 | 6970 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2010 | 1589 | 0.020 |
Why?
|
| Electrocardiography | 2 | 2009 | 6404 | 0.020 |
Why?
|
| Drug Tolerance | 1 | 2007 | 365 | 0.020 |
Why?
|
| Alzheimer Disease | 1 | 2007 | 8726 | 0.020 |
Why?
|
| Exanthema | 1 | 2010 | 501 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2005 | 641 | 0.010 |
Why?
|
| Young Adult | 4 | 2012 | 59870 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2009 | 59526 | 0.010 |
Why?
|
| Massachusetts | 2 | 2010 | 8878 | 0.010 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 14645 | 0.010 |
Why?
|
| Haloperidol | 1 | 2005 | 394 | 0.010 |
Why?
|
| Mood Disorders | 1 | 2010 | 1126 | 0.010 |
Why?
|
| Glycine | 1 | 2007 | 671 | 0.010 |
Why?
|
| Factor Analysis, Statistical | 1 | 2006 | 999 | 0.010 |
Why?
|
| Serine | 1 | 2007 | 824 | 0.010 |
Why?
|
| Apolipoprotein E4 | 1 | 2007 | 707 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2010 | 4015 | 0.010 |
Why?
|
| Outpatients | 1 | 2010 | 1593 | 0.010 |
Why?
|
| Clozapine | 1 | 2005 | 509 | 0.010 |
Why?
|
| Lithium Carbonate | 1 | 2002 | 179 | 0.010 |
Why?
|
| Polyamines | 1 | 1981 | 129 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2009 | 6209 | 0.010 |
Why?
|
| HIV Infections | 1 | 2007 | 17531 | 0.010 |
Why?
|
| Demography | 1 | 2005 | 1641 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2007 | 3623 | 0.010 |
Why?
|
| Social Adjustment | 1 | 2002 | 634 | 0.010 |
Why?
|
| Benzodiazepines | 1 | 2005 | 1135 | 0.010 |
Why?
|
| Child Behavior Disorders | 1 | 2004 | 812 | 0.010 |
Why?
|
| Body Weight | 1 | 2010 | 4624 | 0.010 |
Why?
|
| Age of Onset | 1 | 2006 | 3341 | 0.010 |
Why?
|
| Cardiovascular System | 1 | 2005 | 840 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2007 | 2586 | 0.010 |
Why?
|
| Viral Load | 1 | 2007 | 3385 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2008 | 3045 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2011 | 42481 | 0.010 |
Why?
|
| Animals | 2 | 2008 | 168721 | 0.010 |
Why?
|
| Patient Selection | 1 | 2009 | 4257 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 12060 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2009 | 3479 | 0.010 |
Why?
|
| Alleles | 1 | 2007 | 6893 | 0.010 |
Why?
|
| Affect | 1 | 2003 | 1498 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 12969 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2001 | 2108 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2007 | 9654 | 0.010 |
Why?
|
| Genotype | 1 | 2007 | 13024 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 8040 | 0.010 |
Why?
|
| Mass Screening | 1 | 2006 | 5448 | 0.010 |
Why?
|
| Depression | 1 | 2010 | 8237 | 0.010 |
Why?
|
| Disease Progression | 1 | 2007 | 13615 | 0.010 |
Why?
|
| Seizures | 1 | 1981 | 2999 | 0.000 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2007 | 18065 | 0.000 |
Why?
|
| Peromyscus | 1 | 1981 | 16 | 0.000 |
Why?
|
| Putrescine | 1 | 1981 | 42 | 0.000 |
Why?
|
| Spermidine | 1 | 1981 | 63 | 0.000 |
Why?
|
| Spermine | 1 | 1981 | 70 | 0.000 |
Why?
|
| S-Adenosylhomocysteine | 1 | 1981 | 39 | 0.000 |
Why?
|
| S-Adenosylmethionine | 1 | 1981 | 219 | 0.000 |
Why?
|
| Methionine | 1 | 1981 | 569 | 0.000 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1981 | 1527 | 0.000 |
Why?
|
| Acoustic Stimulation | 1 | 1981 | 1254 | 0.000 |
Why?
|